[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].

This October, the FDA has approved the use of phosphodiesterase inhibitors for the treatment of micurition symptoms due to benign prostatic hyperplasia, so as for erectile dysfunction. This decision is essentially based on the results of 2 studies that we discuss in this article. Although methodologically well designed, these works show that phosphodiesterase inhibitors decrease only weakly, but statistically sigificatively the micturition score of patients suffering from prostatism. Besides that, only one of these papers show a limited effect on a single objective micturitionnal parameter. According to the present knowledge, it appears judicious to prescribe tadalafil to treat benign prostatic hyperplasia symptoms of patients suffering simultaneously of a significant erectile dysfunction.